Table 3

Baseline patient characteristics

Number of patients with prosthetic jointsnbDMARD (n=659)Anti-TNF (n=2689)
Exposure time (years)*195412 959
Incidence prosthetic joint SA/1000 pyrs (95% CI)3.1 (1.1 to 6.7)3.2 (2.3 to 4.3)
Adjusted HR (95% CI)Ref1.2 (0.4 to 3.4)
  • * Patients were included in this analysis only if they had a prosthetic joint in situ.

  • Anti-TNF, anti-tumour necrosis factor; nbDMARD, non-biological disease-modifying antirheumatic drug; pyrs, patient years.